Protagen this week announced the addition of two members to its executive board and one member to its supervisory board.
Joining the executive board are Peter Schulz-Knappe and Martin Blüggel. Schulz-Knappe will take on operational responsibility for the company's diagnostics business unit. He is the former chief scientific officer at Proteome Sciences.
Blüggel will manage the Business Unit Protein Services. He is a co-founder of Protagen and is the chief operating officer.
Thomas Schweins joined the supervisory board. He is a member of the executive committee at Qiagen, where he is also vice president of marketing and strategy.
SDI said this week that Klaus Lindpaintner is joining the firm as chief scientific officer, effective Feb. 1.
Lindpaintner had been with F. Hoffman-La Roche, most recently as director of the Roche Molecular Medicine Laboratories and as Roche's global head of Molecular Medicines Policy and External Affairs, where he coordinated biomarker research based on proteomics, genomics, genetics, and associated disciplines from early discovery to late-stage clinical trials.